Multicenter Study for Evaluation of Efficacy and Safety of Perennial Specific Immunotherapy With a Depot House Dust Mite Allergen Extract (D. Pteronyssinus 100%) in Patients With House Dust Mite Sensitivity

NCT00263549 Phase 4 COMPLETED

The trial is performed to assess efficacy and safety of Novo-Helisen Depot in allergic Rhinoconjunctivitis

Details

Lead sponsor	Allergopharma GmbH & Co. KG
Phase	Phase 4
Status	COMPLETED
Start date	2002-09
Completion	2006-02

Conditions

• House Dust Mite Allergy

Interventions

• House dust mite Novo Helisen Depot

Countries

Germany